An AGTR1 Variant Worsens Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome
Authors:
- 12 March 2019
- journal article
- editorial
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 114 (4) , 556-559
Abstract
S well as nonalcoholic steatohepatitis, fibrosis, dyslipidemia, and insulin resistance. AGTR1 is strongly expressed in adipose, liver, and arteries. The mechanism of this gain-of-function variant is unclear but may include adipose or endothelial dysfunction and immune activation. Despite previous unsuccessful clinical trials of angiotensin receptor blockers in nonalcoholic steatohepatitis, individuals with the rs5186A>C variant may have greater benefit from this therapy....Keywords
This publication has 35 references indexed in Scilit:
- Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adultsAlimentary Pharmacology & Therapeutics, 2011
- Early Inflammatory and Metabolic Changes in Association With AGTR1 Polymorphisms in Prehypertensive SubjectsAmerican Journal of Hypertension, 2011
- Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartanJournal of Clinical Pharmacy and Therapeutics, 2011
- Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat dietClinical Science, 2010
- Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease modelAtherosclerosis, 2009
- Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver diseaseLiver International, 2009
- Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitisWorld Journal of Gastroenterology, 2009
- Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver diseaseHepatology, 2005
- Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitisHepatology, 2004
- Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistanceGut, 2004